Moreover, inhibition of TGFβ signalling in NSCLC by applying Pirfenidone in vitro and in vivo results in reduced proliferation, reduced viability of the tumours, and an increased immune cell influx, suggesting a possible role in therapy [11]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.